

INTEGRA LIFESCIENCES HOLDINGS CORP  
Form 8-K  
August 05, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 4, 2015**

**INTEGRA LIFESCIENCES HOLDINGS CORPORATION**

**(Exact name of Registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of**  
**incorporation or organization)**

**0-26224**  
**(Commission**  
**File Number)**  
**311 Enterprise Drive**

**51-0317849**  
**(I.R.S. Employer**  
**Identification No.)**

**Plainsboro, NJ 08536**

**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (609) 275-0500**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On August 4, 2015, Integra LifeSciences Holdings Corporation (the Company ) priced its previously announced underwritten public offering of 3,300,000 shares of its common stock. The Company has granted the underwriters of the offering an option to purchase up to 495,000 additional shares of its common stock. The offering is expected to be consummated on or about August 10, 2015, subject to certain customary closing conditions. A copy of the press release is attached as Exhibit 99.1 to this report, and is incorporated herein by reference.

**Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

**(d) Exhibits**

99.1 Press Release, dated August 4, 2015, issued by Integra LifeSciences Holdings Corporation.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS  
CORPORATION

Date: August 5, 2015

By: /s/ Glenn G. Coleman  
Glenn G. Coleman

Title: Corporate Vice President and Chief Financial  
Officer

**EXHIBIT INDEX**

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press Release, dated August 4, 2015, issued by Integra LifeSciences Holdings Corporation.